Concepedia

Francesca Carlomagno

FC

Statistics

Publications

68

Citations

7K

H-Index

42

Active since

1992

Affiliations

Institute for Experimental Endocrinology and Oncology(Current)

University of Naples Federico II

University of Reggio Calabria

University of Pisa

Magna Graecia University

Francesca Carlomagno is an author at Institute for Experimental Endocrinology and Oncology specializing in medicine, molecular oncology, and thyroid cancer.

ORCID

Publications per year

1992–2022

68

Publications

68

Activation of <i>RET</i> as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B

Massimo Santoro, Francesca Carlomagno, Alfredo Romano et al. · Science · 1995 · 838 citations

, , +17

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 570 citations

, , +17

BAY 43-9006 Inhibition of Oncogenic RET Mutants

Francesca Carlomagno, Suresh Anaganti, Teresa Guida et al. · JNCI Journal of the National Cancer Institute · 2006 · 471 citations · Full text

, , +17

Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Massimo Santoro, Francesca Carlomagno, Ian Hay et al. · Journal of Clinical Investigation · 1992 · 392 citations · Full text

, , +17

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Fortunato Ciardiello, Rosa Caputo, Vincenzo Damiano et al. · PubMed · 2003 · 329 citations

, , +17

1–5 of 68